PEL-话题@MedSci

#PEL#

39篇内容 | 855人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1625855, encodeId=8c1316258555e, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=Apela基因疗法减轻大鼠肺动脉高压, objectType=article, longId=730570, objectId=796de3057020, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=796de3057020, replyNumber=0, likeNumber=34, createdTime=2022-06-28, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=796de3057020, moduleTitle=Apela基因疗法减轻大鼠肺动脉高压, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=796de3057020)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625854, encodeId=4cc416258545c, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=NEJM Evid：奥拉帕利联合阿比特龙治疗转移性前列腺癌结果公布（PROpel研究）, objectType=article, longId=729571, objectId=1e09e2957129, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e09e2957129, replyNumber=0, likeNumber=38, createdTime=2022-06-16, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e09e2957129, moduleTitle=NEJM Evid：奥拉帕利联合阿比特龙治疗转移性前列腺癌结果公布（PROpel研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e09e2957129)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625853, encodeId=eb31162585302, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=Lancet子刊：评价tezepelumab对激素依赖型哮喘患者的激素节约效应，来自SOURCE 3期研究结果, objectType=article, longId=723558, objectId=c6cae2355856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6cae2355856, replyNumber=0, likeNumber=25, createdTime=2022-04-07, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6cae2355856, moduleTitle=Lancet子刊：评价tezepelumab对激素依赖型哮喘患者的激素节约效应，来自SOURCE 3期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6cae2355856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625852, encodeId=a9ea1625852d7, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=Clin Cancer Res：口服选择性雌激素受体降解剂±Ribociclib或Alpelisib治疗ER+乳腺癌的疗效和安全性, objectType=article, longId=216493, objectId=e168216493b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e168216493b8, replyNumber=0, likeNumber=34, createdTime=2021-09-01, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e168216493b8, moduleTitle=Clin Cancer Res：口服选择性雌激素受体降解剂±Ribociclib或Alpelisib治疗ER+乳腺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e168216493b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625851, encodeId=22df162585171, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌, objectType=article, longId=214659, objectId=4cc12146596f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cc12146596f, replyNumber=0, likeNumber=42, createdTime=2021-07-24, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cc12146596f, moduleTitle=Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cc12146596f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625850, encodeId=59a1162585089, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=Lancet Respirat Med：Tezepelumab对中重度哮喘患者的气道炎性细胞、重塑、高反应性的影响, objectType=article, longId=214141, objectId=513b21414187, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=513b21414187, replyNumber=0, likeNumber=30, createdTime=2021-07-14, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=513b21414187, moduleTitle=Lancet Respirat Med：Tezepelumab对中重度哮喘患者的气道炎性细胞、重塑、高反应性的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=513b21414187)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625849, encodeId=bffd162584901, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=NEJM：TSLP单抗Tezepelumab治疗严重不受控制哮喘III期临床研究获得成功, objectType=article, longId=211275, objectId=f24b2112e55c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f24b2112e55c, replyNumber=0, likeNumber=35, createdTime=2021-05-15, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f24b2112e55c, moduleTitle=NEJM：TSLP单抗Tezepelumab治疗严重不受控制哮喘III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f24b2112e55c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625848, encodeId=46d616258481a, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=哮喘新药显功效！tezepelumab将病情加重风险降低了56％, objectType=article, longId=207707, objectId=e98e20e70755, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e98e20e70755, replyNumber=0, likeNumber=33, createdTime=2021-03-01, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e98e20e70755, moduleTitle=哮喘新药显功效！tezepelumab将病情加重风险降低了56％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e98e20e70755)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625847, encodeId=721b162584ef9, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=Ann Oncol：Alpelisib+氟维司群治疗PIK3CA突变型HR+HER2-晚期乳腺癌的疗效, objectType=article, longId=205897, objectId=fcad20589ed6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcad20589ed6, replyNumber=0, likeNumber=33, createdTime=2021-01-21, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcad20589ed6, moduleTitle=Ann Oncol：Alpelisib+氟维司群治疗PIK3CA突变型HR+HER2-晚期乳腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcad20589ed6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625846, encodeId=624d16258466b, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=阿斯利康的TSLP单抗tezepelumab治疗严重哮喘，III期临床成功, objectType=article, longId=203246, objectId=d0c62032469d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0c62032469d, replyNumber=0, likeNumber=23, createdTime=2020-11-12, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0c62032469d, moduleTitle=阿斯利康的TSLP单抗tezepelumab治疗严重哮喘，III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0c62032469d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625845, encodeId=5297162584541, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=JAMA：耶鲁研究：应用心室辅助装置Impella的院内死亡和大出血风险高, objectType=article, longId=188043, objectId=08ea1880437a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08ea1880437a, replyNumber=0, likeNumber=0, createdTime=2020-02-15, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08ea1880437a, moduleTitle=JAMA：耶鲁研究：应用心室辅助装置Impella的院内死亡和大出血风险高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08ea1880437a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625844, encodeId=bfe8162584477, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=Circulation：Impella在采用机械循环支持的经皮冠状动脉介入治疗患者中的使用、临床预后和费用在近20年来的变化趋势, objectType=article, longId=187112, objectId=2e9d18e11225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e9d18e11225, replyNumber=0, likeNumber=43, createdTime=2020-02-03, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e9d18e11225, moduleTitle=Circulation：Impella在采用机械循环支持的经皮冠状动脉介入治疗患者中的使用、临床预后和费用在近20年来的变化趋势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e9d18e11225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625843, encodeId=c860162584327, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功, objectType=article, longId=185945, objectId=1f6e1859452d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f6e1859452d, replyNumber=0, likeNumber=17, createdTime=2020-01-10, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f6e1859452d, moduleTitle=Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f6e1859452d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625842, encodeId=9365162584249, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=中国NMPA：批准Pellino-1抑制剂BBT-401治疗溃疡性结肠炎的IND, objectType=article, longId=185381, objectId=02de185381c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02de185381c1, replyNumber=0, likeNumber=0, createdTime=2019-12-30, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02de185381c1, moduleTitle=中国NMPA：批准Pellino-1抑制剂BBT-401治疗溃疡性结肠炎的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02de185381c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625841, encodeId=f5d3162584150, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=Blood：ABCC4基因和PEL阴性血型, objectType=article, longId=184698, objectId=9fe8184698b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fe8184698b6, replyNumber=0, likeNumber=39, createdTime=2019-12-14, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fe8184698b6, moduleTitle=Blood：ABCC4基因和PEL阴性血型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fe8184698b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625840, encodeId=2e711625840ca, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=Oncolytics宣布溶瘤病毒Pelareorep与Keytruda联合治疗晚期胰腺癌的阳性1b期REO 024研究结果, objectType=article, longId=182557, objectId=95c618255ecd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95c618255ecd, replyNumber=0, likeNumber=30, createdTime=2019-11-09, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95c618255ecd, moduleTitle=Oncolytics宣布溶瘤病毒Pelareorep与Keytruda联合治疗晚期胰腺癌的阳性1b期REO 024研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95c618255ecd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625839, encodeId=e98f162583966, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=Clinica Chimica Acta：循环生长分化因子-15、kruppel样因子4和生长阻滞剂特异性6与冠心病的关系, objectType=article, longId=181508, objectId=01041815088d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01041815088d, replyNumber=0, likeNumber=39, createdTime=2019-10-19, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01041815088d, moduleTitle=Clinica Chimica Acta：循环生长分化因子-15、kruppel样因子4和生长阻滞剂特异性6与冠心病的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01041815088d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625838, encodeId=99f116258389c, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=**乳腺癌PI3K抑制剂Alpelisib上市，诺华开启乳腺癌分子分型新时代, objectType=article, longId=177001, objectId=9f851e70016d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f851e70016d, replyNumber=0, likeNumber=32, createdTime=2019-08-07, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f851e70016d, moduleTitle=**乳腺癌PI3K抑制剂Alpelisib上市，诺华开启乳腺癌分子分型新时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f851e70016d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625837, encodeId=df66162583e03, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=Stem Cell Res Ther：Apelin部分通过Wnt /β-catenin信号通路增强人骨髓间充质干细胞的成骨分化, objectType=article, longId=174585, objectId=ce2b1e45852e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce2b1e45852e, replyNumber=0, likeNumber=25, createdTime=2019-07-02, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce2b1e45852e, moduleTitle=Stem Cell Res Ther：Apelin部分通过Wnt /β-catenin信号通路增强人骨髓间充质干细胞的成骨分化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce2b1e45852e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1625836, encodeId=9d50162583618, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, objectTitle=J Exp Med：突变的lncRNA Reg1cp对Krüppel样因子3的抑制导致人类高骨量综合征, objectType=article, longId=168534, objectId=cddc1685344d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cddc1685344d, replyNumber=0, likeNumber=41, createdTime=2019-06-17, rootId=0, userName=tidiq, userId=399320916411, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cddc1685344d, moduleTitle=J Exp Med：突变的lncRNA Reg1cp对Krüppel样因子3的抑制导致人类高骨量综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cddc1685344d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PEL

2020-05-29

tidiq (审核中...)

前往app查看评论内容

#PEL#

Apela基因疗法减轻大鼠肺动脉高压

2022-06-28

tidiq (审核中...)

前往app查看评论内容

#PEL#

NEJM Evid：奥拉帕利联合阿比特龙治疗转移性前列腺癌结果公布（PROpel研究）

2022-06-16

tidiq (审核中...)

前往app查看评论内容

#PEL#

Lancet子刊：评价tezepelumab对激素依赖型哮喘患者的激素节约效应，来自SOURCE 3期研究结果

2022-04-07

tidiq (审核中...)

前往app查看评论内容

#PEL#

Clin Cancer Res：口服选择性雌激素受体降解剂±Ribociclib或Alpelisib治疗ER+乳腺癌的疗效和安全性

2021-09-01

tidiq (审核中...)

前往app查看评论内容

#PEL#

Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌

2021-07-24

tidiq (审核中...)

前往app查看评论内容

#PEL#

Lancet Respirat Med：Tezepelumab对中重度哮喘患者的气道炎性细胞、重塑、高反应性的影响

2021-07-14

tidiq (审核中...)

前往app查看评论内容

#PEL#

NEJM：TSLP单抗Tezepelumab治疗严重不受控制哮喘III期临床研究获得成功

2021-05-15

tidiq (审核中...)

前往app查看评论内容

#PEL#

哮喘新药显功效！tezepelumab将病情加重风险降低了56％

2021-03-01

tidiq (审核中...)

前往app查看评论内容

#PEL#

Ann Oncol：Alpelisib+氟维司群治疗PIK3CA突变型HR+HER2-晚期乳腺癌的疗效

2021-01-21

tidiq (审核中...)

前往app查看评论内容

#PEL#

阿斯利康的TSLP单抗tezepelumab治疗严重哮喘，III期临床成功

2020-11-12

tidiq (审核中...)

前往app查看评论内容

#PEL#

JAMA：耶鲁研究：应用心室辅助装置Impella的院内死亡和大出血风险高

2020-02-15

tidiq (审核中...)

前往app查看评论内容

#PEL#

Circulation：Impella在采用机械循环支持的经皮冠状动脉介入治疗患者中的使用、临床预后和费用在近20年来的变化趋势

2020-02-03

tidiq (审核中...)

前往app查看评论内容

#PEL#

Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功

2020-01-10

tidiq (审核中...)

前往app查看评论内容

#PEL#

中国NMPA：批准Pellino-1抑制剂BBT-401治疗溃疡性结肠炎的IND

2019-12-30

tidiq (审核中...)

前往app查看评论内容

#PEL#

Blood：ABCC4基因和PEL阴性血型

2019-12-14

tidiq (审核中...)

前往app查看评论内容

#PEL#

Oncolytics宣布溶瘤病毒Pelareorep与Keytruda联合治疗晚期胰腺癌的阳性1b期REO 024研究结果

2019-11-09

tidiq (审核中...)

前往app查看评论内容

#PEL#

Clinica Chimica Acta：循环生长分化因子-15、kruppel样因子4和生长阻滞剂特异性6与冠心病的关系

2019-10-19

tidiq (审核中...)

前往app查看评论内容

#PEL#

**乳腺癌PI3K抑制剂Alpelisib上市，诺华开启乳腺癌分子分型新时代

2019-08-07

tidiq (审核中...)

前往app查看评论内容

#PEL#

Stem Cell Res Ther：Apelin部分通过Wnt /β-catenin信号通路增强人骨髓间充质干细胞的成骨分化

2019-07-02

tidiq (审核中...)

前往app查看评论内容

#PEL#

J Exp Med：突变的lncRNA Reg1cp对Krüppel样因子3的抑制导致人类高骨量综合征

2019-06-17

科室
- - 订阅+
  - 更多科室
工具
服务